Hanmi Pharm is making significant strides in the obesity and metabolic disease sector,showcasing promising new drug candidates and a renewed focus on research and development.
HM15275: A Triple-action Weight Loss drug
The company has highlighted HM15275, a novel drug that has demonstrated superior weight reduction in animal models compared to existing treatments like Wi Gobi and Beebound. Studies indicated that repeated administration of HM15275 led to greater weight loss. Furthermore, switching to HM15275 after a “double bite” administration also yielded additional weight loss effects. Researchers attribute the efficacy of HM15275 to its triple mechanism, which concurrently promotes energy metabolism and suppresses appetite, thereby contributing to weight loss.
HM17321: Enhancing Body Composition and Metabolic Health
In addition to HM15275, Hanmi Pharm announced three non-clinical studies for HM17321, another innovative drug designed to reduce fat and increase muscle mass.HM17321 has shown significant weight loss and improved body composition in both mouse models and non-human primate models. The drug’s ability to increase muscle mass is particularly noteworthy, as it leads to a higher basal metabolic rate and more efficient metabolism. This dual action of weight reduction and muscle enhancement suggests HM17321 could improve overall quality of life. Moreover, HM17321 has demonstrated potential in improving insulin resistance and regulating blood sugar, indicating its possible application in treating type 2 diabetes. Choi In-young, Director of Hanmi Pharmaceutical’s R&D Center, expressed confidence in the company’s research capabilities, stating they are on par with global pharmaceutical giants in the obesity and metabolic sector.
Strategic Leadership and global Engagement
Hanmi Pharm’s leadership, including owner Lim Joo-hyun, is actively reinforcing the company’s R&D competitiveness. Lim has participated in major international conferences such as the ADA 2025,JP Morgan Healthcare Conference (JPM),and the American Cancer Research Society (AACR) with a team of researchers. These engagements underscore Hanmi Pharm’s commitment to a enduring R&D vision and its ambition to showcase global competitiveness and raise international awareness.
Financial Stability and R&D Investment
Following a year of management disputes, Hanmi Pharm is experiencing a period of stability. The company transitioned to a professional management system in March with the appointment of Kim Jae-kyo as the head of its holding company, Hanmi Science. In the second quarter of the current year,Hanmi Science reported consolidated sales of W33.83 billion and an operating profit of W34.6 billion, marking a 9.4% and 30.7% increase, respectively, compared to the same period last year. Hanmi Pharm itself saw a 4% increase in its second-quarter operating profit, reaching W60.4 billion. The company attributes its performance to successful products like the dyslipidemia treatments ‘Rosujet’ and the ‘Amozal Tan Family’. Hanmi Pharm has demonstrated a strong commitment to innovation, investing W50.4 billion in R&D during the first half of the year, which represents 14% of its sales.
